Magenta Therapeutics Inc (MGTA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139

Magenta Therapeutics, Inc. operates as a bio-technology company. The Company develops medicines, molecules, and cell therapy to transform patient preparation, stem cell expansion, and stem cell harvesting, as well as reduces post-transplant complications. Magenta Therapeutics serves patients in the State of Massachusetts.

Data as of 2020-05-24
Market Cap379.445 Million Shares Outstanding39.484 Million Avg 30-day Volume153.4 Thousand
P/E Ratio Dividend Yield EPS-2.13
Price/Sales Price cash flow ratio Price free cash flow ratio-6.2
Book Value3.18 Price to Tangible Book3.03 Alpha
Short Interest Ratio % Short Interest to Float R-squared
BETA 52-week High/Low17.21 / 5.76 Stddev
View SEC Filings from MGTA instead.

View recent insider trading info

Funds Holding MGTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MGTA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ALBERS JEFFREY W. CEO AND PRESIDENT

  • Officer
  • Director
141,434 2020-05-12 1

DAVIS JOHN C. JR SEE REMARKS

  • Officer
0 2020-04-14 5

BOOTH BRUCE

  • Director
0 2020-04-06 1

BONNEY MICHAEL W

  • Director
0 2020-03-31 2

STANTS KRISTEN CHIEF PEOPLE OFFICER

  • Officer
0 2020-03-02 1

THIRD ROCK VENTURES IV, L.P.

THIRD ROCK VENTURES GP IV, L.P.

TRV GP IV, LLC

  • 10% Owner
1,419,900 2020-02-18 0

BORISY ALEXIS

  • Director
0 2020-02-12 1

ISACSON CHRISTINA K. CHIEF BUSINESS OFFICER

  • Officer
0 2020-02-10 4

GARDNER JASON SEE REMARKS

  • Officer
  • Director
0 2020-02-10 7

ZDRAVESKI ZORAN SEE REMARKS

  • Officer
0 2020-02-10 4

RYAN JASON SEE REMARKS

  • Officer
0 2020-02-10 1

COOKE MICHAEL P. CHIEF SCIENTIFIC OFFICER

240,523 2019-12-02 10

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

  • 10% Owner
4,756,478 2019-07-19 0

DANIEL THOMAS O

  • Director
0 2019-06-26 1

MCGEORGE ANNE

  • Director
0 2019-06-20 2

BYERS BLAKE

  • Director
0 2019-06-07 1

RONNEBERG AMY L

  • Director
0 2019-06-07 1

SCADDEN DAVID

  • Director
0 2019-06-07 1

DRISCOLL CINDY SEE REMARKS

  • Officer
0 2019-01-01 0

GV 2016 GP, L.L.C.

GV 2016 GP, L.P.

GV 2016, L.P.

ALPHABET INC.

  • 10% Owner
No longer subject to file 2018-06-25 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

DAVIS JOHN C. JR - Officer SEE REMARKS

2020-04-14 A 50,000 a 50,000 0.00 direct

Elevate your investments